Pds biotech announces positive clinical data demonstrating compelling survival and clinical responses in recurrent/metastatic hpv-associated cancers published in jama oncology

Median overall survival (mos) of 42.4 months in immune checkpoint inhibitor naÏve patients; historical published result is 7-12 months continued survival in the cohort of hpv16-positive immune checkpoint inhibitor naÏve patients - mos not yet reached median os of 17 months in hpv16-positive immune checkpoint inhibitor resistant patients; historically published result is 3-4 months significant tumor shrinkage with confirmed objective response rate (orr) of 75% in hpv16-positive immune checkpoint inhibitor naÏve patients; historically published result is 11-24% princeton, n.j., feb. 26, 2025 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of clinical results in the journal of the american medical association (jama) oncology.
PDS Ratings Summary
PDS Quant Ranking